What the label states, the lot delivers — net peptide mass, not gross powder weight, purity reported as measured rather than rounded up, and a Certificate of Analysis for every lot.
Net peptide mass, not powder weight; purity as measured, not rounded up; a COA per lot.
Net peptide + purity not rounded up. COA per lot.
FDA PCAC reviews 7 peptides for the 503A bulks list (BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, Epitalon). Read our compounder's decision tree. Read our briefing →
FDA PCAC reviews 7 peptides for the 503A bulks list in July. Read →
FDA PCAC: 7 peptides under review. Read →
GIP/GLP incretin blend · weight-management research
Overview
This research preparation combines Retatrutide (LY3437943, a triple GLP-1/GIP/glucagon receptor agonist) and Tirzepatide (LY3298176, a dual GIP/GLP-1 receptor agonist) in a single vial at a fixed 20 mg + 40 mg ratio. Both are incretin-mimetic peptides with independent Phase 3 clinical data for their individual effects; the fixed combination itself has not been evaluated in a dedicated clinical trial and is supplied for research use only. Vialdyne co-formulates Retatrutide + Tirzepatide (Blend) to the stated ratio and releases it with a batch-specific Certificate of Analysis reporting per-component identity, RP-HPLC purity, and fill accuracy. The component breakdown is documented on the lot COA.
Applications & buyer fit
Custom-blend buyers are almost always OEM clients building a branded product around a specific ratio of two or more peptides. The development workflow is collaborative: ratio target, analytical method to verify it, stability protocol in the chosen carrier, and packaging selection are all defined in the OEM brief before the first commercial run. Sample-stage volumes are usually 5-10 g of finished blend; commercial MOQ depends on the components.
Sourced for
Buyer fit
Documentation that ships
Procurement note: Ratio target, the analytical method to verify it, stability protocol, and packaging are defined in the OEM brief before the first commercial run.
Primary buyer fit: academic and contract research laboratories.
Specifications
Regulatory note
Research-use-only reference material; not for human or veterinary use.
Frequently asked questions
Retatrutide + Tirzepatide (Blend) ships as white lyophilized powder with a batch-specific Certificate of Analysis reporting RP-HPLC purity (See per-component COA), mass-spec identity, and appearance. Recommended storage: -20°C; reconstituted 2–8°C. Supplied strictly as a research reference material — not for human or veterinary use.
Related peptides
GIP / GLP-1 / glucagon tri-agonist
GIP / GLP-1 dual receptor agonist
Cagrilintide + Semaglutide combination
